Performance for the Fiscal Year under Review

FY2024 Overview*

	Digital Solutions Business	Plastics Business	Life Sciences Business
Net Sales	**215.7** billion yen (YoY **+28**%)	**93.3** billion yen (YoY **+1**%)	**80.9** billion yen (YoY **−38**%)
Core Operating Profit	**43.1** billion yen (YoY **+113**%)	**1.3** billion yen (YoY **−13**%)	**−38.7** billion yen (YoY N/A)
Main Companies	●JSR ●JSR Micro Kyushu Co., Ltd. ●JSR Micro, Inc. ●JSR Micro N.V. ●Inpria Corporation ●JSR Electronic Materials Korea Co., Ltd. ●JSR Electronic Materials Taiwan Co., Ltd. ●JSR Electronic Materials (Shanghai) Co., Ltd. ●YAMANAKA HUTECH CORPORATION ●JSR (Shanghai) Co., Ltd. ●JSR Micro (Changshu) Co., Ltd. ●JSR Micro Korea Co., Ltd. ●JSR Micro Taiwan Co., Ltd. ●JSR ARTON Manufacturing Co., Ltd.	●Techno-UMG Co., Ltd. ●JAPAN COLORING CO., LTD.	●JSR ●KBI Biopharma, Inc. ●Crown Bioscience International ●JSR North America Holdings, Inc. ●JSR Life Sciences, LLC
Number of Employees	**2,843** persons	**1,131** persons	**3,285** persons
Review of FY2024	**Electronic Materials Business** This business proceeded smoothly in FY2024. Although overall semiconductor demand lacked strength in general purpose fields, demand from AI and other cutting-edge fields was extremely robust. JSR's product lineup covers a wide range of processes related to semiconductor manufacturing. In FY2024, we further expanded our product portfolio by acquiring a company that offers ALD precursors with a history of adoption among cutting-edge users. **Display Solution Business, Optical Solution Business** Despite a temporary adjustment, the demand climate remained positive throughout FY2024. Sales of LCD alignment layer, passivation coats, mobile OLED materials, phase retardation film resins, smartphone camera optical films, and other mainstay products in both businesses grew steadily.	The Plastics Business faced sluggish demand from the domestic automotive industry and industrial materials field. Despite this environment, we worked to improve profitability and develop new application areas.	The Life Sciences Business continued to experience lower profits in FY2024, while structural reforms were still a work in progress. We decided to pause operations at the newly built CDMO plant in North Carolina, United States, as a means of addressing quality issues, and focused on improving maintenance and production processes. This move resulted in a significant decline in sales, which had a major impact on performance.
Performance Trends			

* As of March 31, 2025

Note: JSR transferred Medical & Biological Laboratories Co., Ltd., and JSR Life Sciences Corporation to Tokuyama Corporation on October 1, 2025.